This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

I have mentioned before that mmg does track the ftse but with exaggerated swings.

In my opinion there is no other reason for today's slip other then simply the market maliase of today............. very good buying opportunity!

I would have increased my holding but got into Cobra Bio. this a.m instead.

I have not tracked the market today but looking at the mmg trades it was gaining strength throughout the afternoon, even when the DOW & NASDAQ where opening down.

I think we may creep up again tomorrow by one or two %.

Good luck.. Rob

take a look at the 1 year chart guys, see what has happened of late after a slip.....

Dow down 150 points and the FTSE down 30 points so not a good day overall and as Rob says MMG does indeed track the Ftse but they managed to recover slightly in the afternoon again tracking the Ftse..hold on.

Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the results is expected by March 2005.
Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.
Watch this space.

After hours trading on the NAZ was up, with some big Tech heavyweights giving strong news. Might not be as bad in the morning as some were predicting this afternoon.

cheers GF.

After hours trading on the NAZ was up, with some big Tech heavyweights giving strong news. Might not be as bad in the morning as some were predicting this afternoon.

cheers GF.

Dont sell off, the markets getting a shock taste of reality. There will be a bounce in the US.

cheers GF.

Its a general market thing and the MM's are taking advantage of the situation..there short and looking to buy back at lower levels(isnt everybody) but try not to fall into their trap.Holding up quite well considering.

Yes I agree Mitzy. This just came out from Killik brokers might be a good idea to paste it around........................................

Sentiment in the near term appears to have turned with active profit taking in the second liners after a terrific run to the start of the year. How far things will come back is the obvious key question but so far, it does not appear as if too much stock is coming out and this feels more like a healthy correction rather than something more significant.

cheers GF.

Bounce back in the FTSE, lets hope we'll see a turn around in the small caps too.

Bouncing off lows now...

Yup only 1p down now.

cheers GF.

Excelent news just out and one reason for the recovery. Snobby broker firm just given out the following................


"...Insinger de Beaufort London have issued a research note today with a short term price target of 200p. This is on the basis of the Genvax news and the current negotiating with potential licensee companies for the ruthenium technology".

Buy buy buy.

cheers GF.

Now back at evens for the day.

cheers GF.

There is speculation that the DNA platform technology company Genvax could be a World beater and be a bigger earner than the Ruthenium technology but I am not convinced until the March evaluation results..watch this space.

I have no complaints about today with mmg..... I have suffered elsewhere but thankfully not here... stay in. Rob

We had a great bullish reversal today with the sp down initially and then making a come-back in the afternoon..if this pattern continues tomorrow we could see more buyers returning and the sp climbing higher once again.
Hopefully good news from Ruthenium and Genvax within the next 4 weeks will push this to 200p as per the latest brokers note which gf mentioned today.Next a licencing deal with a big pharma will give MMG the financial consideration it deserves and the sp will push even higher than before.

I agree totaly.

cheers GF.

gf.
If the Ruthenium drug gets to market in 3 years time we could have a real winner on our hands, and a share price to match...1500p easily in 2009...and Genvax could add another 500p..

Yes and I still think your target of 400p could be on the cards for the end of this year.

cheers GF.

23 February 2005
Latest News In Life Sciences



MMI further expands collaboration
By Business Weekly, 22 February 2005, viewed 37 times, emailed 26 times


Medical Marketing International Group plc, the Cambridge pharmaceutical development company has further expanded the collaboration between the University of Edinburgh and its wholly owned subsidiary Oncosense.


Medical Marketing International Group plc, the Cambridge pharmaceutical development company has further expanded the collaboration between the University of Edinburgh and its wholly owned subsidiary Oncosense.

The team developing Ruthenium anticancer complexes will now include Dr James Hoeschele a co-inventor of the best selling platinum based chemotherapy drug Carboplatin.

Dr Hoeschele, an acknowledged expert in the field of anti-tumour precious metal complexes, has more than 30 years experience working in both industry and academia.

He is named as inventor on 12 patents relating to platinum based complexes used as chemotherapy agents and has published 50 reviewed scientific papers on platinum based chemotherapy drugs including studies of pharmacokinetics, biodistribution and their structure activity relationships.

Prof Peter Sadler and Dr Duncan Jodrell, the inventors of the Ruthenium based anti-cancer drugs, have shown that certain ruthenium complexes appear to have significant advantages over platinum-based drugs that are widely used in the clinic.

Oncosense is funding Prof Sadlers department to achieve commercial targets in the development of Ruthenium compounds.

cheers GF.